Michael Bauer, Ph.D. Email & Phone Number

Vienna, AT

QUANTRO Therapeutics GmbH is a privately funded research company that strives to discover and develop novel effective therapeutics that interfere with disease-causing transcriptional programs in cancer and other diseases.Based on proprietary transcriptional signatures, QUANTRO will assemble a highly innovative drug-discovery pipeline that employs.

I am an experienced Biotech Entrepreneur and Executive with a proven track record as CEO, Member of the Board of Directors, and other senior leadership roles. Overall, I have gained more than 25 years’ leadership, development, research, and regulatory experience in the life sciences industry. I brought several innovative oncology drugs with new modes of.

Basel, Basel-Town, CH

As Co-founder, CEO and member of Cellestia Board of Directors I have advanced a single-molecule post-doc research project into a pioneering Oncology R&D Ph2 clinical stage company targeting new modes of action, closely integrating the drug development, diagnostic approaches for patient selection and response tracking, implementing a successful global Ph2.

Allschwil, CH

Leading Drug Development at Polyphor, a broad portfolio covering several drug development programs in a wide range of different indications, e.g. Oncology, Antibiotics, Hematology, Cardiology, Inflammatory Diseases, reaching a strong proof of concept in Oncology opening the path for Ph 3.

Basel, Baselstadt, CH

Senior Program Manager and Portfolio Manager for global drug development programs of novel Anti-Cancer Drugs (both small molecule and biologics) in a wide range of solid tumor (e.g. NSCLC, mBC, aGC etc.) and hematological malignancies(e.g. AML, MM, etc). Responsible for global development programs ranging from late pre-clinical development to Translational.

Project Leader in Preclinical and Clinical Drug Development (Pharma/Biotech)- responsible for preclinical development of different novel antibiotics (iv and topical therapy), successful implementation of IND enabling program- responsible for clinical development of oral dose form of iclaprim (Phase I, preparation phase II)- active contribution to NDA & MAA.

Basel, Basel, CH

Key responsibilities:- Leading multi project global development programs - Team size ranges from 10-60 people plus associated sub-teams- New compound development and life cycle management programs- Manage annual R&D budget of ca $20-60 million on projects with associated sales of ca. $600 million p.a. - Lead Development Portfolio Strategy Team- Manage.

Basel, Basel, CH

Develop and implement regulatory strategy for assigned product portfolio. Product range including blockbusters, divestments, re-registration and new formulation development.Key Achievements:- Development and execution of global regulatory strategies for assigned portfolio, strategic regulatory leadership to business in International Project Teams.- Led.

- Lead a team of scientists and technicians as line manager, laboratory head & study director. Monitoring of contracted–out studies. - Represent the company at international industry work-groups and authorities.- Lead interdisciplinary metabolism research projects aiming to streamline the safety assessments for human and environmental safety and optimise.

Screening, isolation and characterisation of thermophilic microorganisms able to degrade xenobiotic organic compounds; Elucidation of degradation pathway; Purification and characterisation of proteins involved in phenol degradation; Assay development for protein detection; PCR, Molecular cloning and bioinformatic analysis of sequence;

Doctorate, Biotechnology

Diploma Chemistry, Analytical Chemistry